Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Dupixent is now annualizing at close to €6.0 billion in sales after around five years on the market. Sanofi expects Dupixent to achieve more than €13 billion in peak sales.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication. By Zacks Equity Research, Entrepreneur.comJan 21, 2022 ...

Paris and Tarrytown, NY – April 3, 2020 – The pivotal Phase 3 clinical trial results announced today show Dupixent ® (dupilumab) combined with standard-of-care topical corticosteroids (TCS ...